Fund Overview
Activity Summary — 2026 Q1
Top Buys
| Stock | % Impact |
|---|---|
| SCHR SCHWAB INTERMED.. | +5.39% |
| PULS PGIM ULTRA SHOR.. | +5.01% |
| JPLD JPMORGAN LIMITE.. | +3.13% |
| SGOV ISHARES 0-3 MON.. | +3.03% |
| CLOA ISHARES AAA CLO.. | +0.81% |
| XONE BONDBLOXX BLOOM.. | +0.77% |
Top Sells
| Stock | % Impact |
|---|---|
| VMBS VANGUARD MORTGA.. | -4.31% |
| VTIP VANGUARD SHORT-.. | -0.54% |
| VTI VANGUARD TOTAL .. | -0.45% |
| VGT VANGUARD INFORM.. | -0.36% |
| PCMM BONDBLOXX PRIVA.. | -0.30% |
| IVV ISHARES CORE S&.. | -0.28% |
Activity Summary
Sector Allocation Trends
Holdings Analysis
Positions Dynamics
Portfolio Analytics — Latest
Bulwark Capital Corp risk dashboard covering volatility, beta, value-at-risk, drawdowns, concentration, factor tilts, benchmark comparison, and stress testing for the latest disclosed portfolio.
Tracking institutional benchmark deviation
Best Strategy vs. Benchmarks
Strategy Backtester: Bulwark Capital Corp
Replicate top holdings performance • Compare vs benchmarks • Optimize N
Find the best N! Test multiple portfolio sizes at once to discover the optimal configuration.
Risk insights! Identify periods when the fund lagged the benchmark – critical for timing entries.
⏱ Run Backtest
Liquid Glass Edition
👆 Click the button to launch tickers!
Backtesting Bulwark Capital Corp's top 10 holdings against SPY identified 2 underperformance periods. Worst drawdown: 2025-07 – 2025-11 (-5.1% vs SPY, 5 quarters).
The ticker-level breakdown shows how each of Bulwark Capital Corp's top holdings contributed to portfolio returns quarter by quarter. Strongest recent contributors inside the last 5 years of the quarterly Top 10 backtest window: VTI (2025 Q2 – 2025 Q4, +1.5 pts), IVV (2025 Q2 – 2025 Q4, +1.0 pts), VMBS (2025 Q2 – 2025 Q4, +0.6 pts), VGT (2025 Q2 – 2025 Q4, +0.5 pts), VTIP (2025 Q2 – 2025 Q4, +0.3 pts) .
Disclaimer: 13Foresight is not a registered investment adviser, broker-dealer, or financial planner. All information on this site is provided solely for informational and educational purposes and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Portfolio backtests shown on this page are hypothetical and simulated — they do not represent actual trading results and were constructed with the benefit of hindsight. Actual results would differ materially. 13F filings disclose only long equity positions valued above $10,000, submitted up to 45 days after quarter-end; they do not capture short positions, options, bonds, cash, private investments, or non-U.S. securities. A fund's backtest performance may not reflect its actual returns, as managers frequently generate alpha through strategies not visible in 13F data. Past performance is not indicative of future results. All data sourced from public SEC EDGAR filings. Use at your own risk. Full Terms of Use.